Generic Name and Formulations:
Doxycycline 40mg (30mg immediate-release beads, 10mg delayed-release beads); caps.
Galderma Laboratories, Inc.
Indications for ORACEA:
Treatment of inflammatory lesions (papules and pustules) of rosacea. Limitations of use: this formulation has not been evaluated in the treatment or prevention of infections. Efficacy >16 weeks and safety >9 months have not been established.
Take on empty stomach in the morning with sufficient amount of fluids. 40mg once daily.
Do not substitute with other doxycycline products. Renal impairment. Hepatic insufficiency. Monitor blood, renal and hepatic function. Achlorhydria. GI surgery. Predisposition to candidiasis overgrowth. Avoid sun and UV light. Discontinue if pseudomembranous colitis or superinfection occurs and treat appropriately. Monitor for autoimmune syndromes. Labor & delivery. Pregnancy (Cat.D), nursing mothers: not recommended. Not recommended for either gender if conception is planned.
Avoid concomitant methoxyflurane, penicillins, photosensitizers, oral retinoids. Reduced absorption with bismuth subsalicylate, acid pump inhibitors, antacids, calcium, magnesium, iron. May potentiate anticoagulants (eg, warfarin). May antagonize hormonal contraceptives (use back-up contraception). May be antagonized by metabolic enzyme inducers (eg, barbiturates, carbamazepine, phenytoin).
Nasopharyngitis, sinusitis, superinfection, diarrhea, dry mouth, hypertension, blood glucose increase, elevated liver enzymes or BUN; pseudomembranous colitis, autoimmune syndromes (discontinue if occurs), hyperpigmentation, photosensitivity; benign intracranial hypertension, teeth discoloration, others (see full labeling).
Renal and Urology News Articles
- Kidney Damage in Younger Adults Tied to NSAID Use
- Dialysis and Transplant Patients at Increased Risk for Cancer Death
- Guidelines Updated for Pulmonary Arterial Hypertension in Adults
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Darolutamide Improves Metastasis-Free Survival in CRPC
- Prednisone to Blame for ERA 223 Trial Failure?
- Clinicians Somewhat Favor Shared Decision-Making in Older mCRPC Patients
- Higher Push-Up Capacity Linked to Lower Incidence of CVD Events
- Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer
- Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)